

**Supplemental Table 1. Reports of long-term trials of valproate for bipolar disorder**

Report	Dx	Design	Treatment Arms	Duration (months)	Total N
Bowden et al. (2000) <sup>32</sup>	BD-I	RCT	VPA vs. PBO or Li	12.0	372
Gyulai et al. (2003) <sup>33</sup>	BD-I	RCT	VPA vs. PBO or Li	12.0	372
Tohen et al. (2003) <sup>34</sup>	BD-I	RCT	VPA vs. ONZ	11.8	251
Calabrese et al. (2005) <sup>35</sup>	BD-I+II	RCT	VPA vs. Li	20.0	60
Altamura et al. (2008) <sup>36</sup>	BD-I+II	Open	VPA vs. Li, LTG or QTP	48.0	184
Langosch et al. (2008) <sup>37</sup>	BD-I+II	ROT	VPA vs. QTP	12.0	37
McElroy et al. (2008) <sup>38</sup>	BD-I	RCT	VPA vs. PBO or Li	12.0	369
Geddes et al. (2010) <sup>39</sup>	BD-I	ROT	VPA vs. Li or Li+VPA	24.0	220
Kessing et al. (2011) <sup>40</sup>	BD-I+II	Open	VPA vs. Li	33.3	1845
Hayes et al. (2016) <sup>41</sup>	BD-I+II	Open	VPA vs. Li, ONZ or QTP	38.7	5089
Peselow et al. (2016) <sup>42</sup>	BD-I	Open	VPA vs. Li or CBZ	124	225
Rosso et al. (2017) <sup>43</sup>	BD-I+II	Open	VPA vs. Li	18.0	57
Kang et al. (2020) <sup>44</sup>	BD-I	RCT	VPA vs. Li	12.0	159

*Abbreviations:* BD, bipolar disorder, types I or II; CBZ, carbamazepine; Dx, diagnosis; Li, lithium carbonate; LTG, lamotrigine; ONZ, olanzapine; Open, nonrandomized, unblinded trial; PBO, placebo; QTP, quetiapine; RCT, randomized, controlled trial; ROT, randomized, unblinded trial; VPA, valproate (usually divalproex). The grand total N=9240 in the 13 trials, and trial-duration averaged 29.1 [10.4–47.7] months.